Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop ...

The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb’s ...

EpimAb_Logo Planegg/Martinsried and Shanghai, February 27, 2025. (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic ...

Inside, the cabin features Black/Night Blue Merino leather M Carbon bucket seats trimmed in Sao Paulo Yellow, with the VR46 logo embroidered ... oversaw a fleet of Audi TCR race cars, ziptied ...

Stepping up to the Quattro adds a full suite of S-Line bodywork with black interior headlining as well as 20-inch Audi Sport alloys, sport leather seats with the S logo, a three-spoke ... 180kW/370Nm; ...

Offered in the 8518 and 8536 case sizes, WSBE series devices feature a proprietary processing technique that produces their extremely low resistance values. Combined with high power ratings and ...

The "TCR Therapy - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.The T-cell receptor (TCR) therapy landscape has been comprehensively detailed, showcasing a ...

“On the heels of our recently announced positive Phase 2a data in patients living with psoriasis, we look forward to continuing to evaluate the potential of Nck modulation to impact TCR signaling ...

The multi-target collaboration combines the respective expertise of each company with Medigene's 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb's ...

SINGAPORE, Feb. 11, 2025 /PRNewswire/ -- On 12 Feb 2025 (Singapore Time), Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.